TRINITY BIOTECH PLC-SPON ADR (TRIB) Fundamental Analysis & Valuation
NASDAQ:TRIB • US8964385046
Current stock price
0.6042 USD
0 (-0.2%)
At close:
0.6043 USD
+0 (+0.02%)
After Hours:
This TRIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TRIB Profitability Analysis
1.1 Basic Checks
- TRIB had negative earnings in the past year.
- In the past year TRIB has reported a negative cash flow from operations.
- TRIB had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
1.2 Ratios
- TRIB's Return On Assets of -31.91% is on the low side compared to the rest of the industry. TRIB is outperformed by 60.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.91% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of TRIB (34.83%) is worse than 72.87% of its industry peers.
- TRIB's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
2. TRIB Health Analysis
2.1 Basic Checks
- TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TRIB remains at a similar level compared to 1 year ago.
- TRIB has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for TRIB has been reduced compared to a year ago.
2.2 Solvency
- TRIB has an Altman-Z score of -1.17. This is a bad value and indicates that TRIB is not financially healthy and even has some risk of bankruptcy.
- TRIB has a Altman-Z score of -1.17. This is comparable to the rest of the industry: TRIB outperforms 40.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.17 |
ROIC/WACCN/A
WACC6.92%
2.3 Liquidity
- TRIB has a Current Ratio of 1.05. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.05, TRIB is doing worse than 88.83% of the companies in the same industry.
- A Quick Ratio of 0.41 indicates that TRIB may have some problems paying its short term obligations.
- TRIB's Quick ratio of 0.41 is on the low side compared to the rest of the industry. TRIB is outperformed by 92.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.41 |
3. TRIB Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 41.07% over the past year.
- TRIB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.31%.
- Measured over the past years, TRIB shows a decrease in Revenue. The Revenue has been decreasing by -7.41% on average per year.
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.04%
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%16.15%
3.2 Future
- The Earnings Per Share is expected to grow by 34.68% on average over the next years. This is a very strong growth
- Based on estimates for the next years, TRIB will show a quite strong growth in Revenue. The Revenue will grow by 11.62% on average per year.
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. TRIB Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TRIB. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as TRIB's earnings are expected to grow with 34.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.68%
EPS Next 3YN/A
5. TRIB Dividend Analysis
5.1 Amount
- No dividends for TRIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TRIB Fundamentals: All Metrics, Ratios and Statistics
0.6042
0 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-06 2026-04-06/bmo
Earnings (Next)N/A N/A
Inst Owners4.55%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap11.42M
Revenue(TTM)61.55M
Net Income(TTM)-31.79M
Analysts85.71
Price TargetN/A
Short Float %26.25%
Short Ratio0.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.26
BVpS-2.62
TBVpS-5.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.91% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.83% | ||
| FCFM | N/A |
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
F-Score2
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 405.1% | ||
| Cap/Sales | 15.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -1.17 |
F-Score2
WACC6.92%
ROIC/WACCN/A
Cap/Depr(3y)316%
Cap/Depr(5y)319.23%
Cap/Sales(3y)10.22%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.04%
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%16.15%
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.1%
OCF growth 3YN/A
OCF growth 5YN/A
TRINITY BIOTECH PLC-SPON ADR / TRIB Fundamental Analysis FAQ
What is the fundamental rating for TRIB stock?
ChartMill assigns a fundamental rating of 1 / 10 to TRIB.
Can you provide the valuation status for TRINITY BIOTECH PLC-SPON ADR?
ChartMill assigns a valuation rating of 1 / 10 to TRINITY BIOTECH PLC-SPON ADR (TRIB). This can be considered as Overvalued.
What is the profitability of TRIB stock?
TRINITY BIOTECH PLC-SPON ADR (TRIB) has a profitability rating of 0 / 10.
What is the financial health of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
The financial health rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 1 / 10.
How sustainable is the dividend of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
The dividend rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 0 / 10 and the dividend payout ratio is 0%.